NCT04327700 2026-03-05
Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib
Wake Forest University Health Sciences
Phase 2 Terminated
Clinical Trials
66 trialsNCT03785210 2026-02-23
Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT04258566 2026-02-02
Electromagnetic Tracking and Optical Imaging With ICG for Hepatic Biopsies
National Institutes of Health Clinical Center (CC)
Phase NA Terminated
NCT05256381 2025-11-17
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
Sotio Biotech Inc.
Phase 2 Terminated
NCT02881554 2025-10-29
Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or Metastatic Liver Cancer Undergoing Radiation Therapy or Surgery
University of Washington
Phase NA Terminated
NCT04050462 2025-10-16
Nivolumab Combined With BMS-986253 in HCC Patients
NYU Langone Health
Phase 2 Terminated
NCT05009979 2025-08-28
18F-DCFPyL PET/CT in Hepatocellular Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT03534141 2025-05-16
MHALT
University of California, San Francisco
Phase NA Terminated
NCT04732286 2025-05-08
A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy
Hoffmann-La Roche
Phase 3 Terminated
NCT04629339 2025-03-13
Study of INCB086550 in Select Solid Tumors
Incyte Corporation
Phase 2 Terminated
NCT03812289 2025-03-07
Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer
OHSU Knight Cancer Institute
Phase NA Terminated
NCT01205828 2025-02-12
ABT-888 and Temozolomide for Liver Cancer
Georgetown University
Phase 2 Terminated
NCT05653427 2025-01-13
A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma
Janssen Research & Development, LLC
Phase 2 Terminated
NCT00687596 2024-09-19
Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy
Taiho Oncology, Inc.
Phase 2 Terminated
NCT03960008 2024-08-28
SBRTvsTACE
Lahey Clinic
Phase 3 Terminated
NCT02314052 2024-07-11
Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma
Novo Nordisk A/S
Phase 1/2 Terminated
NCT04541173 2024-06-05
Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Hoosier Cancer Research Network
Phase 2 Terminated
NCT02762266 2024-03-12
Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization
Stanford University
Phase 3 Terminated
NCT03397342 2024-01-18
MRI Only Radiation Therapy With CPAP
Albert Einstein College of Medicine
Phase NA Terminated
NCT03422679 2024-01-16
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
Cellestia Biotech AG
Phase 1/2 Terminated
NCT04235660 2023-10-25
SBRT vs Y90
Indiana University
Phase NA Terminated
NCT05249569 2023-05-03
Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma
University of Texas Southwestern Medical Center
Phase 2 Terminated
NCT01433016 2022-12-20
OBT for HCC
Meridian Bioscience, Inc.
Phase 2 Terminated
NCT03781960 2022-12-14
Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma
Abramson Cancer Center at Penn Medicine
Phase 2 Terminated
NCT02575339 2022-07-26
MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma
Big Ten Cancer Research Consortium
Phase 1/2 Terminated
NCT00746590 2022-07-21
Study of Anti-tumour Effects and Safety of Prolarixâ„¢ in Hepatocellular Carcinoma
BTG International Inc.
Phase 2 Terminated
NCT03402607 2022-07-08
PROVE-HCC
Duke University
Phase NA Terminated
NCT01402908 2022-06-23
PATRON
Cellxpert Biotechnology Corp.
Phase 3 Terminated
NCT01387932 2021-11-30
HiQuality
Merit Medical Systems, Inc.
Phase 3 Terminated
NCT03071094 2021-11-19
A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)
Transgene
Phase 1/2 Terminated
NCT01141478 2021-10-15
HCC
Loma Linda University
Phase NA Terminated
NCT04099277 2021-08-31
A Study of LY3435151 in Participants With Solid Tumors
Eli Lilly and Company
Phase 1 Terminated
NCT01032850 2021-06-02
Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT01887717 2021-04-21
YES-P
Boston Scientific Corporation
Phase 3 Terminated
NCT02460991 2021-02-12
SOLACE
Boston Scientific Corporation
Phase 3 Terminated
NCT01821963 2020-09-24
Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)
M.D. Anderson Cancer Center
Phase 3 Terminated
NCT02013778 2020-04-20
Phase 1-2 Trial HCQ Plus TACE in Unresectable HCC
Abramson Cancer Center at Penn Medicine
Phase 1/2 Terminated
NCT03433703 2019-12-06
Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)
Eisai Inc.
Phase 2 Terminated
NCT02147301 2019-09-10
TACE Using Doxorubicin-eluting Beads for Patients With HCC and Marginal Hepatic Reserve
University of California, San Francisco
Phase NA Terminated
NCT01806740 2019-08-08
DCE-MRI
Guerbet
Phase 4 Terminated
NCT01465464 2019-08-07
ORIENTAL
Taiho Pharmaceutical Co., Ltd.
Phase 3 Terminated
NCT01290523 2019-05-13
Yttrium-90 Radioembolization With Glass Microspheres (TheraSphere) for Patients With Hepatocellular Carcinoma
University of California, San Francisco
Phase NA Terminated
NCT02950025 2019-04-03
Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary or Oligometastatic Abdominal Malignancies
Washington University School of Medicine
Phase 2 Terminated
NCT02828124 2019-01-30
A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT02057874 2018-07-11
3-Tesla MRI Response to TACE in HCC (Liver Cancer)
Vanderbilt-Ingram Cancer Center
Phase NA Terminated
NCT00832637 2018-06-29
Gem-ox
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT00459108 2018-04-19
Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00903396 2017-11-24
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Terminated
NCT02549755 2017-11-22
11C-acetate for Treatment Response After Radiotherapy for HCC
Indiana University
Phase 2 Terminated
NCT01668017 2017-08-23
A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy
Merck KGaA, Darmstadt, Germany
Phase 1 Terminated